Clinical trial
Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
NCT00224393 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00224393 |
|---|---|
| Title | Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis |
| Lead sponsor | The Cleveland Clinic, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Systemic Amyloidosis |
| Intervention type | Drug |
| Interventions | Enbrel |
| Enrollment | 60 |
| Start date | Feb 1, 2001 |
| Completion | Aug 31, 2005 |
| First posted | Sep 23, 2005 |
| Last update posted | May 30, 2023 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: